Literature DB >> 22622600

Unfavourable outcome of deep brain stimulation in a Tourette patient with severe comorbidity.

A Duits, L Ackermans, D Cath, V Visser-Vandewalle.   

Abstract

Entities:  

Mesh:

Year:  2012        PMID: 22622600      PMCID: PMC3432784          DOI: 10.1007/s00787-012-0285-6

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


× No keyword cloud information.
Dear Editor(s), In 1999, deep brain stimulation (DBS) was introduced as a new therapeutic approach for intractable Tourette syndrome (TS) [1]. Currently, it is still considered to be an experimental option with limited controlled data to support its effect [2, 3]. Both single and multiple brain areas have been targeted to deal with tics as well as comorbid symptoms of TS, including attention deficit hyperactivity disorder (ADHD), obsessive–compulsive disorder (OCD) and behaviour (OCb), self-injurious behaviour (SIB), depression and anxiety. These associated comorbidities are present in up to 90 % of clinically referred TS patients and have a significant impact on quality of life [2]. So far, guidelines to select patients [4, 5] for DBS were mainly focused on tics. Also in the recently revised clinical guidelines by the European Society for the Study of Tourette Syndrome [2], the issue comorbidity in patient selection is relatively underaddressed. In 2010, we have completed a double-blind trial stimulating the centromedian nucleus–substantia periventricularis nucleus–ventro-oralis internus (Cm–Spv–Voi) cross-point of the thalamus [3]. Here, we report on the outcome of DBS in an institutionalized patient with intractable TS and severe comorbidity. Although she was younger than 25 years, she was included in the trial and underwent surgery for clinical urgency. Postoperatively, she could not be randomised within the period of follow-up because of unexplained complications. In this letter, we discuss the nature of the complications and the implications for patient selection. The 20-year-old female patient was born with a mild spastic diplegia due to complications during pregnancy. The diagnosis of TS was made at the age of 10 years. Motor and vocal tics included eye blinking, licking, cheek biting, tapping with her right foot, coughing, barking, uttering sounds and coprolalia. Associated comorbidities included depression, pervasive developmental disorder not otherwise specified (PDD-NOS) and compulsions (e.g., forced touching of furniture and a specific form of trichotillomania). In 2005, she developed severe SIB, including repetitive hitting her head and arm (she had to wear a helmet and a body protector), poking sharp objects into her body and scratching until bleeding. Numerous pharmacological treatments had been administrated and discontinued, due to the side effects or lack of response. Behavioural therapy and electroconvulsive therapy were even leading to new tics. In November 2006, she underwent surgery for thalamic DBS. See Ackermans and colleagues [3] for the surgical details. Three weeks after surgery, while adjusting the parameters, the patient showed an abrupt onset of severe hypertonia in her left leg. In the following days, this extended to the right leg and both arms, followed by involuntary movements of the left arm, and on one occasion rotating movements of both arms above the head. The symptoms did not disappear when switching off the stimulator. Either with or without stimulation, the hypertonia was present but inconsistent over time and could not be classified within the phenomenology of organic movement disorders such as myoclonus, dystonia or spasticity. During the first month after surgery, she was bedridden and developed an opisthotonus. Rehabilitation with a cognitive behavioural approach was not successful. In May 2007 she developed unexplained disturbances of consciousness, followed by periods of mutism. To exclude a side-effect of stimulation, double-blind stimulation was performed at 19 months after surgery according to the procedure of the trial [3]. Unblinding the conditions showed an increase in tics (see Table 1), but a relief of hypertonia while the stimulator was switched on, and visa versa. For the patient, the results were completely unexpected and she decided to have the stimulator switched off. From that time on she showed alternating hypertonia in legs and arms, but relatively few motor and vocal tics. Later, she developed complaints of impaired swallowing, nausea and she could not bear food anymore. Diagnostics (e.g., gastroscopy) did not result in an organic explanation and psychiatric consultation did not reveal a depressive state. Hypodermoclysis could not prevent dehydration and she refrained from admission to a hospital for intravenous infusion. In November 2009, she passed away in a nursing home. For personal reasons no autopsy was performed.
Table 1

Pre- and post-operative assessment of tics and comorbidities

Before surgerya Stimulation offb Stimulation onc
Tic severity (YGTSS total)421239
Vocal tics (YGTSS vocal)17014
Motor tics (YGTSS motor)251225
OCD (Y-BOCS)2087
SIB (VAS)5.708.9
ADHD (CAARS)584245
Autism (PDD-SQ)136127124
Depression (BDI-II)122015
Anxiety (BAI)324144

YGTSS Yale Global Tic Severity Scale, OCD obsessive compulsive disorder, Y-BOCS Yale-Brown Obsessive Compulsive Scale, SIB self injurious behaviour, VAS Visual Analogue Scale, ADHD attention deficit hyperactivity disorder, CAARS Conners Adult ADHD Rating Scale, PDD-SQ Pervasive Developmental Disorder-Self Questionnaire, BDI-II Beck Depression Inventory (2nd edn.), BAI Beck Anxiety Inventory

aPre-operative medication included duloxetin (30 mg/day), alprazolam (0.50 mg 4 times a day), baclofen (20 mg thrice a day) and pergolide (0.05 mg/day)

b22 months after surgery, at the end of the first randomization period of 3 months with stimulation ‘off’

c23 months after surgery, at the end of the second randomization period of only 6 weeks with stimulation ‘on’ and the following stimulation parameters: 5 mV, 60 μs and 110 Hz (contact 1−/2+, 5−/6+) bilaterally

Pre- and post-operative assessment of tics and comorbidities YGTSS Yale Global Tic Severity Scale, OCD obsessive compulsive disorder, Y-BOCS Yale-Brown Obsessive Compulsive Scale, SIB self injurious behaviour, VAS Visual Analogue Scale, ADHD attention deficit hyperactivity disorder, CAARS Conners Adult ADHD Rating Scale, PDD-SQ Pervasive Developmental Disorder-Self Questionnaire, BDI-II Beck Depression Inventory (2nd edn.), BAI Beck Anxiety Inventory aPre-operative medication included duloxetin (30 mg/day), alprazolam (0.50 mg 4 times a day), baclofen (20 mg thrice a day) and pergolide (0.05 mg/day) b22 months after surgery, at the end of the first randomization period of 3 months with stimulation ‘off’ c23 months after surgery, at the end of the second randomization period of only 6 weeks with stimulation ‘on’ and the following stimulation parameters: 5 mV, 60 μs and 110 Hz (contact 1−/2+, 5−/6+) bilaterally Considering the criteria of Fahn and Williams [6], the abrupt onset of the hypertonia, its inconsistency and incongruency with organic disorders, the bizarre movements and the concomitant somatizations (loss of consciousness, mutism and later swallowing disturbances) suggest a psychogenic movement disorder. The surgical procedure or stimulation may have caused a dysbalance in the limbic and associative cortico-basal ganglia-thalamocortical loops [7], leading to psychiatric symptoms. Perhaps, the symptoms could be seen as disinhibition or progression of a preoperatively unidentified somatoform disorder. Reviewing the patient’s medical history, it is noteworthy that she frequently suffered from abdominal distress, headaches and unexplained urine retention (related to decreased relaxation of pelvic muscles). Finally, the decrease in tic severity, which possibly served as a coping mechanism to daily demands prior to surgery, might have interfered with the results of DBS. Although it is difficult to draw final conclusions, we believe that the course of this case illustrates the potential contra-indication for DBS in TS patients with severe comorbidity. While TS is a heterogeneous entity [8], the combination of associated comorbidities with prominent and severe SIB may raise questions about the diagnosis. Whereas the diagnosis of TS had been approved by several experts in TS prior to surgery, our patient might also have suffered from an additional somatoform disorder. A somatoform disorder can be treatment-resistent as well, but contrary to TS, DBS is not indicated and might even worsen the clinical picture. Apart from the psychiatric comorbidity, our patient also suffered from a pre-existent neurological disorder, spastic diplegia, which in itself may constitute a risk for DBS. In conclusion, before deciding upon DBS, we would like to emphasize that experts in TS should confirm the diagnosis and that patients should be thoroughly screened for somatoform disorder, including psychogenic movement disorder. Patients should be excluded from DBS in the presence of symptoms. Overall, clinicians should be alert on comorbid psychiatric symptoms beyond the well-known associated comorbidities such as OCD and ADHD. Serious preoperative attempts to treat psychiatric comorbidities are warranted even in case of apparent clinical urgency to perform surgery.
  8 in total

1.  Stereotactic treatment of Gilles de la Tourette syndrome by high frequency stimulation of thalamus.

Authors:  V Vandewalle; C van der Linden; H J Groenewegen; J Caemaert
Journal:  Lancet       Date:  1999-02-27       Impact factor: 79.321

Review 2.  Deep brain stimulation: from neurology to psychiatry?

Authors:  Paul Krack; Marwan I Hariz; Christelle Baunez; Jorge Guridi; Jose A Obeso
Journal:  Trends Neurosci       Date:  2010-09-09       Impact factor: 13.837

3.  Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome.

Authors:  Jonathan W Mink; John Walkup; Kirk A Frey; Peter Como; Danielle Cath; Mahlon R Delong; Gerald Erenberg; Joseph Jankovic; Jorge Juncos; James F Leckman; Neal Swerdlow; Veerle Visser-Vandewalle; Jerrold L Vitek
Journal:  Mov Disord       Date:  2006-11       Impact factor: 10.338

4.  European clinical guidelines for Tourette syndrome and other tic disorders. Part IV: deep brain stimulation.

Authors:  Kirsten R Müller-Vahl; Danielle C Cath; Andrea E Cavanna; Sandra Dehning; Mauro Porta; Mary M Robertson; Veerle Visser-Vandewalle
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-04       Impact factor: 4.785

5.  Psychogenic dystonia.

Authors:  S Fahn; D T Williams
Journal:  Adv Neurol       Date:  1988

6.  Double-blind clinical trial of thalamic stimulation in patients with Tourette syndrome.

Authors:  Linda Ackermans; Annelien Duits; Chris van der Linden; Marina Tijssen; Koen Schruers; Yasin Temel; Mariska Kleijer; Pieter Nederveen; Richard Bruggeman; Selma Tromp; Vivianne van Kranen-Mastenbroek; Herman Kingma; Danielle Cath; Veerle Visser-Vandewalle
Journal:  Brain       Date:  2011-03       Impact factor: 13.501

7.  Dissecting the Gilles de la Tourette spectrum: a factor analytic study on 639 patients.

Authors:  Andrea E Cavanna; Hugo D Critchley; Michael Orth; Jeremy S Stern; Mary-Beth Young; Mary M Robertson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-03-24       Impact factor: 10.154

8.  Deep brain stimulation in Gilles de la Tourette's syndrome.

Authors:  Veerle Visser-Vandewalle; Linda Ackermans; Chris van der Linden; Yasin Temel; Marina A Tijssen; Koen R J Schruers; P Nederveen; M Kleijer; P Boon; W Weber; D Cath
Journal:  Neurosurgery       Date:  2006-03       Impact factor: 4.654

  8 in total
  7 in total

Review 1.  Deep brain stimulation for psychiatric diseases: what are the risks?

Authors:  Christian Saleh; Denys Fontaine
Journal:  Curr Psychiatry Rep       Date:  2015-05       Impact factor: 5.285

Review 2.  Uncommon applications of deep brain stimulation in hyperkinetic movement disorders.

Authors:  Kara M Smith; Meredith A Spindler
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2015-02-02

Review 3.  Deep Brain Stimulation for Tourette's Syndrome: The Case for Targeting the Thalamic Centromedian-Parafascicular Complex.

Authors:  Paola Testini; Hoon-Ki Min; Asif Bashir; Kendall H Lee
Journal:  Front Neurol       Date:  2016-11-10       Impact factor: 4.003

4.  Target-Specific Effects of Deep Brain Stimulation for Tourette Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Laura Wehmeyer; Thomas Schüller; Jana Kiess; Petra Heiden; Veerle Visser-Vandewalle; Juan Carlos Baldermann; Pablo Andrade
Journal:  Front Neurol       Date:  2021-10-20       Impact factor: 4.086

5.  The International Deep Brain Stimulation Registry and Database for Gilles de la Tourette Syndrome: How Does It Work?

Authors:  Wissam Deeb; Peter J Rossi; Mauro Porta; Veerle Visser-Vandewalle; Domenico Servello; Peter Silburn; Terry Coyne; James F Leckman; Thomas Foltynie; Marwan Hariz; Eileen M Joyce; Ludvic Zrinzo; Zinovia Kefalopoulou; Marie-Laure Welter; Carine Karachi; Luc Mallet; Jean-Luc Houeto; Joohi Shahed-Jimenez; Fan-Gang Meng; Bryan T Klassen; Alon Y Mogilner; Michael H Pourfar; Jens Kuhn; L Ackermans; Takanobu Kaido; Yasin Temel; Robert E Gross; Harrison C Walker; Andres M Lozano; Suketu M Khandhar; Benjamin L Walter; Ellen Walter; Zoltan Mari; Barbara K Changizi; Elena Moro; Juan C Baldermann; Daniel Huys; S Elizabeth Zauber; Lauren E Schrock; Jian-Guo Zhang; Wei Hu; Kelly D Foote; Kyle Rizer; Jonathan W Mink; Douglas W Woods; Aysegul Gunduz; Michael S Okun
Journal:  Front Neurosci       Date:  2016-04-25       Impact factor: 4.677

Review 6.  The Use of Deep Brain Stimulation in Tourette Syndrome.

Authors:  Ladan Akbarian-Tefaghi; Ludvic Zrinzo; Thomas Foltynie
Journal:  Brain Sci       Date:  2016-08-19

7.  Ethics of Deep Brain Stimulation in Adolescent Patients with Refractory Tourette Syndrome: a Systematic Review and Two Case Discussions.

Authors:  Anouk Y J M Smeets; A A Duits; D Horstkötter; C Verdellen; G de Wert; Y Temel; L Ackermans; A F G Leentjens
Journal:  Neuroethics       Date:  2018-03-23       Impact factor: 1.480

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.